Reinfecção pelo Toxoplasma gondii Nicolle & Manceaux, 1909 em camundongos e gatos: estudo experimental

Experimental reinfection by Toxoplasma gondii in 27 albino mice and 25 domestic cats was studied. Tachyzoites and cysts of AS28 and N strains, by peritoneal and oral route were used. Infection and reinfection were demonstrated by clinical signs, by dye-test and by shedding of oocysts (cats). Mortality of mice was 56%. Infection by the AS28 strain, with low virulence, chronic evolution and cysts in brain, gave some protection to reinfection, manifested by a lower mortality (12.5%) and mice survival. The same occurred when a virulent strain was attenuated by administration of Sulfamonometoxine. Domestic cats were reinfected by ingestion of Toxoplasma cysts, in spite of the presence of a first infection with tachyzoites or cysts by peritoneal or oral via. Mortality was 28% between 4 and 7 1/2 months after infection. After reinfection 48% had higher titers, 44% had unchanged titers and 8% had lower titers. Oocyst shedding after the first infection was 60%, oocyst reshedding was 25%. After the third infection there was no elimination. Shedding of oocysts was observed only after administration of cysts by oral route. Presence of previous serum antibodies of maternal or post-infection origin had no influence neither on immunological response nor on oocysts elimination. Parasites were recovered on 88.2% of the cats and were more frequent in mesenteric lymphonodes and in small intestine; in this organ Toxoplasma was present around 14 months after infection. Wellnouri- shed cats presented ascending titers in dye-test, oocysts shedding in 72% of the animals and reshedding in 30%. Malnourished cats presented low or descending titers, oocysts elimination in 28,5% and no reelimination. Experimental reinfection of cats by Toxoplasma gondii was obtained but the reshedding was infrequent and with fewer oocysts.A reinfecção pelo Toxoplasma gondii foi estudada, experimentalmente, em 27 camundongos albinos e 25 gatos domésticos. A infecção e a reinfecção foram comprovadas por sinais clínicos, anticorpos sangüíneos à reação de Sabin & Feldman >; 1/4, recuperação do parasita e, nos gatos, também pela eliminação de oocistos. Nos camundongos a mortalidade foi de 56%. A primo-infecção por cepa de baixa virulência ou a infecção por cepa mais virulenta, atenuada pela sulfamonometoxina, deram proteção à reinfecção por cepa mais virulenta, mortal em poucos dias. Esta proteção foi demonstrada pela sobrevivência de camundongos e menor mortalidade, 12,5'%. Nos gatos a mortalidade foi de 28%, A resposta sorológica à primo-infecção ocorreu em todos. Após a reinfecção houve elevação de títulos em 64% dos gatos, permanência em 32% e queda em 4%. A eliminação de oocistos foi observada em 60% dos gatos e só após inoculação de cistos, por via digestiva. A reeliminação após reinfecção, ocorreu em 25% dos gatos. Não foi observada eliminação após a 3.ª inoculação. Em 88,2% dos gatos houve recuperação do parasita em camundongo, mais freqüente nos linfonodos mesentéricos e no intestino delgado, persistindo neste cerca de 14 meses. Foi constatada certa relação entre o bom estado físico dos gatos e a resposta sorológica, a eliminação e a reeliminação de oocistos. Apesar da persistência de anticorpos sangüíneos a reinfecção experimental dos gatos foi observada, porém a reeliminação de oocistos foi pouco freqüente e em pequena quantidade

In cis TP53 and RAD51C pathogenic variants may predispose to sebaceous gland carcinomas

Pathogenic variants in TP53 have been classically thought to cause Li-Fraumeni syndrome (LFS), a cancer predisposition with high risks for various childhood- and adult-onset malignancies. However, increased genetic testing has lately revealed, that pathogenic variant carriers exhibit a broader range of phenotypes and that penetrance may be dependent both on variant type and modifiers. Using next generation sequencing and short tandem repeat analysis, we identified germline pathogenic variants in TP53 and RAD51C located in cis on chromosome 17 in a 43-year-old male, who has developed a rare sebaceous gland carcinoma (SGC) but so far no tumors of the LFS spectrum. This course mirrors a Trp53-Rad51c-double-mutant cis mouse-model, which similarly develops SGC, while the characteristic Trp53-associated tumor spectrum occurs with significantly lower frequency. Therefore, we propose that co-occurent pathogenic variants in RAD51C and TP53 may predispose to SGC, reminiscent of Muir-Torre syndrome. Further, this report supports the diversity of clinical presentations associated with germline TP53 alterations, and thus, the proposed expansion of LFS to heritable TP53-related cancer syndrome

De Novo Missense Variants in SLC32A1 Cause a Developmental and Epileptic Encephalopathy Due to Impaired GABAergic Neurotransmission

Objective:Rare inherited missense variants inSLC32A1, the gene that encodes the vesicular gamma-aminobutyric acid(GABA) transporter, have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarifyif de novo missense variants inSLC32A1can also cause epilepsy with impaired neurodevelopment.Methods:Using exome sequencing, we identified four individuals with a developmental and epileptic encephalopathyand de novo missense variants inSLC32A1. To assess causality, we performed functional evaluation of the identifiedvariants in a murine neuronal cell culture model.Results:The main phenotype comprises moderate-to-severe intellectual disability, infantile-onset epilepsy within thefirst 18 months of life, and a choreiform, dystonic, or dyskinetic movement disorder. In silico modeling and functionalanalyses reveal that three of these variants, which are located in helices that line the putative GABA transport pathway,result in reduced quantal size, consistent with impairedfilling of synaptic vesicles with GABA. The fourth variant,located in the vesicular gamma-aminobutyric acid N-terminus, does not affect quantal size, but increases presynapticrelease probability, leading to more severe synaptic depression during high-frequency stimulation. Thus, variants invesicular gamma-aminobutyric acid can impair GABAergic neurotransmission through at least two mechanisms, byaffecting synaptic vesiclefilling and by altering synaptic short-term plasticity.Interpretation:This work establishes de novo missense variants inSLC32A1as a novel cause of a developmental andepileptic encephalopathy

Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1

Pontocerebellar hypoplasia (PCH) describes a group of rare heterogeneous neurodegenerative diseases with prenatal onset. Here we describe eight children with PCH from four unrelated families harboring the homozygous MINPP1 (NM_004897.4) variants; c.75_94del, p.(Leu27Argfs*39), c.851 C > A, p.(Ala284Asp), c.1210 C > T, p.(Arg404*), and c.992 T > G, p.(Ile331Ser). The homozygous p.(Leu27Argfs*39) change is predicted to result in a complete absence of MINPP1. The p.(Arg404*) would likely lead to a nonsense mediated decay, or alternatively, a loss of several secondary structure elements impairing protein folding. The missense p.(Ala284Asp) affects a buried, hydrophobic residue within the globular domain. The introduction of aspartic acid is energetically highly unfavorable and therefore predicted to cause a significant reduction in protein stability. The missense p.(Ile331Ser) affects the tight hydrophobic interactions of the isoleucine by the disruption of the polar side chain of serine, destabilizing the structure of MINPP1. The overlap of the above-mentioned genotypes and phenotypes is highly improbable by chance. MINPP1 is the only enzyme that hydrolyses inositol phosphates in the endoplasmic reticulum lumen and several studies support its role in stress induced apoptosis. The pathomechanism explaining the disease mechanism remains unknown, however several others genes of the inositol phosphatase metabolism (e.g., INPP5K, FIG4, INPP5E, ITPR1) are correlated with phenotypes of neurodevelopmental disorders. Taken together, we present MINPP1 as a novel autosomal recessive pontocerebellar hypoplasia gene

Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1.

Pontocerebellar hypoplasia (PCH) describes a group of rare heterogeneous neurodegenerative diseases with prenatal onset. Here we describe eight children with PCH from four unrelated families harboring the homozygous MINPP1 (NM_004897.4) variants; c.75_94del, p.(Leu27Argfs*39), c.851 C > A, p.(Ala284Asp), c.1210 C > T, p.(Arg404*), and c.992 T > G, p.(Ile331Ser). The homozygous p.(Leu27Argfs*39) change is predicted to result in a complete absence of MINPP1. The p.(Arg404*) would likely lead to a nonsense mediated decay, or alternatively, a loss of several secondary structure elements impairing protein folding. The missense p.(Ala284Asp) affects a buried, hydrophobic residue within the globular domain. The introduction of aspartic acid is energetically highly unfavorable and therefore predicted to cause a significant reduction in protein stability. The missense p.(Ile331Ser) affects the tight hydrophobic interactions of the isoleucine by the disruption of the polar side chain of serine, destabilizing the structure of MINPP1. The overlap of the above-mentioned genotypes and phenotypes is highly improbable by chance. MINPP1 is the only enzyme that hydrolyses inositol phosphates in the endoplasmic reticulum lumen and several studies support its role in stress induced apoptosis. The pathomechanism explaining the disease mechanism remains unknown, however several others genes of the inositol phosphatase metabolism (e.g., INPP5K, FIG4, INPP5E, ITPR1) are correlated with phenotypes of neurodevelopmental disorders. Taken together, we present MINPP1 as a novel autosomal recessive pontocerebellar hypoplasia gene

Altered gene expression profiles impair the nervous system development in individuals with 15q13.3 microdeletion

The 15q13.3 microdeletion has pleiotropic effects ranging from apparently healthy to severely affected individuals. The underlying basis of the variable phenotype remains elusive. We analyzed gene expression using blood from three individuals with 15q13.3 microdeletion and brain cortex tissue from ten mice Df[h15q13]/+. We assessed differentially expressed genes (DEGs), protein–protein interaction (PPI) functional modules, and gene expression in brain developmental stages. The deleted genes’ haploinsufficiency was not transcriptionally compensated, suggesting a dosage effect may contribute to the pathomechanism. DEGs shared between tested individuals and a corresponding mouse model show a significant overlap including genes involved in monogenic neurodevelopmental disorders. Yet, network-wide dysregulatory effects suggest the phenotype is not caused by a single critical gene. A significant proportion of blood DEGs, silenced in adult brain, have maximum expression during the prenatal brain development. Based on DEGs and their PPI partners we identified altered functional modules related to developmental processes, including nervous system development. We show that the 15q13.3 microdeletion has a ubiquitous impact on the transcriptome pattern, especially dysregulation of genes involved in brain development. The high phenotypic variability seen in 15q13.3 microdeletion could stem from an increased vulnerability during brain development, instead of a specific pathomechanism

Prevalência de toxoplasmose ovina determinada pela reação de Sabin-Feldman em animais de Uruguaiana, RS, Brasil

The sera from 100 ovines from Uruguaiana (Rio Grande do Sul, Brazil), slaughtered in Bragança Paulista (S. Paulo, Brazil), were examined for the presence of antibodies against Toxoplasma gondii using the Sabin-Feldman dye test. Considering positive those sera with titer >; or = 16, the prevalence of this zoonosis was 39% with titers and percentages of seropositivity of: 16 (66.7%), 64 (23%), 256 (2.6%), 1024 (5.1%) and 4000 (2.6%).Determinou-se a prevalência de toxoplasmose ovina em soros de 100 animais, provenientes de Uruguaiana, RS e abatidos em Bragança Paulista, SP, Brasil, através de reação de Sabin-Feldman (RSF). Considerando-se animais positivos aqueles com títulos >; ou = 16, obtiveram-se 39% de soro-reagentes, com títulos e percentuais de soropositividade correspondentes a: 16 (66,7%), 64 (23%), 256 (2,6%), 1024 (5,1) e 4000 (2,6%)